Denna sida på svenska
Loading profile information...

About me

Assoc. Professor of Experimental Cardiology

Education

1999                    Biochemical-pharmacist - Faculty of Pharmaceutical Sciences, University of São Paulo (USP), Riberião Preto, Brazil.

2005                    PhD in immunology. Institute of Biomedical Sciences, University of São Paulo (USP), São Paulo, Brazil.

2005 – 2010        Postdoctoral fellow, Experimental Cardiovascular Research Unit, CMM, Karolinska University Hospital, Stockholm, Sweden.

Research description

Cardiovascular diseases (CVDs) are the leading cause of mortality and disability worldwide, imposing a significant burden on society. Coronary heart disease and cerebrovascular disease, the two most common forms of cardiovascular disease, are caused by acute complications of atherosclerosis. CVD kills over 17 million individuals every year, which accounts for one third of all global deaths.

Although population-wide management of traditional risk factors for CVDs (e.g. hyperlipidemia, high-blood pressure, glycaemia) has reduced the incidence of cardiovascular events in developed countries, substantial residual risk remains. Thus, translational therapeutic strategies targeting novel molecular pathways regulating atherosclerosis are needed. 

Atherosclerosis is a chronic inflammatory disease initiated by retention and accumulation of lipids in the artery wall, especially low-density lipoprotein (LDL), leading to maladaptive responses of innate and adaptive immune cells. Notably, metabolism and activation are fully integrated in immune cells, and systemic or microenvironmental changes in metabolism have been shown to modulate their responses.

In pioneer work, we have identified several targets to modulate the unwanted immune responses in the artery wall, including components of LDL that can trigger innate and adaptive immune cells, and metabolites of the essential amino acid tryptophan, via the Kynurenine pathway. Our research indicates that metabolites are not just ‘fuels’ in their metabolic pathways, but that they can also act as signalling molecules in immune cells and influence atherosclerosis. By increasing the understanding of the immunometabolic reactions controlling immune responses in atherogenesis, our research will lead to the development of new drugs to treat and prevent atherosclerotic CVDs.

Selected publications

28194913

28420668

26892965

25848033

25750192 

24816772 

23903754

22711758

22064596 

20439543

Loading publication list...